Q-omics provides the consensus-scored CLDN10 profile across patient tissues and cancer cell-line models. CLDN10 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CLDN10 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CLDN10 protein abundance shows 16,651 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where CLDN10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLDN10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLDN10 survival associations across molecular data types. CLDN10 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLDN10 RNA expression–survival associations across cancer types. High CLDN10 expression shows unfavorable associations in BLCA, STAD and ACC, but favorable associations in KIRC, UCEC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CLDN10 RNA expression.
This table summarizes CLDN10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CLDN10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLDN10 shows lower tumor expression in KIRC, KICH, KIRP and HNSC and higher tumor expression in THCA and LUAD. The KIRC box plot shows higher CLDN10 RNA expression in normal versus tumor tissue (log2 FC = −2.357, t-test p < 0.001).
This table shows molecular features associated with CLDN10 in patient tissues and cancer cell lines. In patient samples, CLDN10 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CLDN10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
